These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
| | |
Important Notice Regarding the Availability of Proxy Materials for
the Shareholders Meeting to Be Held on November 18, 2022 |
| |
| | |
The Notice of Meeting, the Circular, and form of proxy are available on the internet at the following website: investors.vireohealth.com/financials/regulatory-filings/
|
| |
| | | |
Page
|
| |||
| | | | | | | | |
| | | | | | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 11 | | | |
| | | | | 15 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 28 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 31 | | | |
| | | | | 32 | | | |
| | | | | 33 | | | |
| | | | | 33 | | | |
| | | | | 33 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 35 | | | |
| | | | | 36 | | | |
| | | This Circular includes forward-looking statements. These statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. For a discussion of some of the risks and important factors that could affect the Goodness Growth’s business, operations, future results and financial condition, see “Risk Factors” in Goodness Growth’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the “SEC”) on March 15, 2022, as amended by Amendment No. 1 on Form 10-K/A, filed with the SEC on April 29, 2022 (collectively, the “2021 Annual Report”). | | |
| |
Proposal 1
|
| | To fix the number of directors for the ensuing year at seven, subject to such increases as may be permitted by Goodness Growth’s articles of incorporation (the “Goodness Articles”) | |
| |
Proposal 2
|
| | To elect the seven nominees proposed by management of Goodness Growth as directors of Goodness Growth for the ensuing year | |
| |
Proposal 3
|
| | To appoint Davidson & Company LLP as the auditors of Goodness Growth for the ensuing year and to authorize the Board to fix their remuneration; and | |
| |
Proposal 4
|
| | To transact such further or other business as may properly come before the Meeting or any other adjournments or postponements thereof. | |
| |
No.
|
| |
Proposal
|
| |
Votes Necessary
|
|
| | 1. | | | Setting the Number of Directors Proposal | | |
Approval requires the affirmative vote of a majority of the votes cast by the holders of Goodness Shares present in person or represented by proxy and entitled to vote at the Meeting, voting together as a single class.
Abstentions and broker non-votes will not be counted as votes cast and will have no effect on the outcome of the voting on the Setting the Number of Directors Proposal.
|
|
| | 2. | | | Director Election Proposal | | |
Approval requires the affirmative vote of a majority of the votes cast by the holders of Goodness Shares present in person or represented by proxy and entitled to vote at the Meeting, voting together as a single class.
Abstentions and broker non-votes will not be counted as votes cast and will have no effect on the outcome of the voting on the Director Election Proposal.
|
|
| | 3. | | | Auditors Appointment Proposal | | |
Approval requires the affirmative vote of a majority of the votes cast by the holders of Goodness Shares present in person or represented by proxy and entitled to vote at the Meeting, voting together as a single class.
Abstentions and broker non-votes will not be counted as votes cast and will have no effect on the outcome of the voting on the Auditors Appointment Proposal.
|
|
| | |
Important Notice Regarding the Availability of Proxy Materials for the
Meeting of Shareholders to Be Held on November 18, 2022: |
| |
| | |
This Circular and the 2021 Annual Report are available free of charge at: investors.vireohealth.com/financials/regulatory-filings/.
|
| |
|
Name of Nominee
|
| |
Director
Since |
| |
Residency
|
| |
Principal Occupation(1)
|
|
| Dr. Kyle E. Kingsley | | | March 2019 | | |
Minnesota, USA
|
| | Founder and Chief Executive Officer of Goodness Growth and Chair of the Board | |
|
Chelsea A. Grayson(2)(3)(4)
|
| | March 2019 | | |
California, USA
|
| | Executive-in-Residence, Wunderkind (formerly BounceX) | |
| Ross M. Hussey(3)(4) | | | July 2020 | | |
Minnesota, USA
|
| |
Attorney, Smith Jadin Johnson, PLLC
|
|
| Victor E. Mancebo(2)(3)(4) | | | January 2021 | | | Florida, USA | | | Chief Executive Officer, TheraTrue, Inc. | |
| Judd T. Nordquist(2) | | | March 2019 | | |
Minnesota, USA
|
| | CPA and Partner, Abdo L.L.P. | |
| Josh Rosen | | | August 2021 | | | Arizona, USA | | | Managing Partner, Bengal Capital | |
| Amber H. Shimpa(4) | | | March 2019 | | |
Minnesota, USA
|
| | Chief Administrative Officer of Goodness Growth | |
|
Name
|
| |
Age*
|
| |
Position
|
|
| Dr. Kyle E. Kingsley | | |
47
|
| | Chief Executive Officer and Chair of the Board | |
| Chelsea A. Grayson | | |
50
|
| | Director | |
| Ross M. Hussey | | |
44
|
| | Director | |
| Victor E. Mancebo | | |
38
|
| | Director | |
| Judd T. Nordquist | | |
52
|
| | Director | |
| Josh Rosen | | |
49
|
| | Director | |
| Amber H. Shimpa | | |
43
|
| | Chief Administrative Officer and Director | |
| Dr. Stephen Dahmer | | |
47
|
| | Chief Medical Officer | |
| John A. Heller | | |
54
|
| | Chief Financial Officer | |
| Christian Gonzalez | | |
41
|
| | Chief Operating Officer | |
| Patrick Peters | | |
48
|
| | Executive Vice President, Retail | |
| Harris Rabin | | |
47
|
| | Chief Marketing Officer | |
| J. Michael Schroeder | | |
55
|
| | General Counsel, Chief Compliance Officer, and Secretary | |
|
Director Name
|
| |
Audit Committee
|
| |
Compensation Committee
|
| |
N&G Committee
|
|
| Dr. Kyle Kingsley | | | | | | | | | | |
| Chelsea Grayson | | |
Member
|
| |
Member
|
| |
Chair
|
|
| Ross Hussey | | | | | |
Chair
|
| |
Member
|
|
| Victor Mancebo | | |
Member
|
| |
Member
|
| |
Member
|
|
| Judd Nordquist | | |
Chair
|
| | | | | | |
| Josh Rosen | | | | | | | | | | |
| Amber Shimpa | | | | | | | | |
Member
|
|
|
Name and Principal Position
|
| |
Fees
Earned or Paid in Cash ($) |
| |
Option
Awards ($)(1) |
| |
Stock
Awards ($) |
| |
Total ($)
|
| ||||||||||||
|
Chelsea A. Grayson
|
| | | | 71,000 | | | | | | 98,683 | | | | | | 58,711 | | | | | | 228,394 | | |
|
Ross M. Hussey
|
| | | | 71,000 | | | | | | 37,580 | | | | | | 58,711 | | | | | | 167,291 | | |
|
Victor E. Mancebo(2)
|
| | | | 68,042 | | | | | | 37,507 | | | | | | 58,711 | | | | | | 164,260 | | |
|
Judd T. Nordquist
|
| | | | 71,000 | | | | | | 87,683 | | | | | | 58,711 | | | | | | 217,394 | | |
|
Josh Rosen(3)
|
| | | | 27,204 | | | | | | 25,000 | | | | | | 29,320 | | | | | | 81,524 | | |
|
Plan Category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights |
| |
Weighted-
average exercise price of outstanding options, warrants and rights |
| |
Number of
securities remaining available for future issuance under equity compensation plans |
| |||||||||
|
Equity compensation plans approved by security holders
|
| | | | 7,205,496 | | | | | $ | 1.14 | | | | | | 5,605,637 | | |
|
Equity compensation plans not approved by security holders
|
| | | | 16,020,842 | | | | | $ | 0.30 | | | | | | — | | |
|
Total
|
| | | | 23,226,338 | | | | | $ | 0.47 | | | | | | 5,605,637 | | |
|
Name and Principal Position
|
| |
Year
|
| |
Salary ($)
|
| |
Option
Awards ($) |
| |
All Other
Compensation ($)(1) |
| |
Total ($)
|
| |||||||||||||||
|
Dr. Kyle E. Kingsley
Chief Executive Officer |
| | | | 2021 | | | | | | 360,000 | | | | | | — | | | | | | 176 | | | | | | 360,176 | | |
| | | | 2020 | | | | | | 295,269 | | | | | | — | | | | | | 176 | | | | | | 295,445 | | | ||
|
John A. Heller
Chief Financial Officer |
| | | | 2021 | | | | | | 300,000 | | | | | | — | | | | | | 176 | | | | | | 300,176 | | |
| | | | 2020 | | | | | | 133,333 | | | | | | 827,249 | | | | | | 176 | | | | | | 960,758 | | | ||
|
Christian Gonzalez
Chief Operating Officer |
| | | | 2021 | | | | | | 250,000 | | | | | | — | | | | | | 176 | | | | | | 250,176 | | |
| | | | 2020 | | | | | | 217,150 | | | | | | 486,783 | | | | | | — | | | | | | 703,933 | | | ||
|
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| ||||||||||||
|
Dr. Kyle E. Kingsley
|
| | | | 5,063,315 | | | | | | 37,506(1) | | | | | | — | | | | | $ | 0.33 | | | |
May 1, 2023
|
|
|
John A. Heller
|
| | | | 410,919 | | | | | | 904,022(2) | | | | | | — | | | | | $ | 0.77 | | | |
September 10, 2030
|
|
|
Christian Gonzalez
|
| | | | 125,000 | | | | | | 375,000(3) | | | | | | — | | | | | $ | 1.19 | | | |
November 29, 2030
|
|
| | | | | | 150,000 | | | | | | 150,000(4) | | | | | | — | | | | | $ | 1.13 | | | |
December 2, 2029
|
|
| | | | | | 112,518 | | | | | | 37,506(5) | | | | | | — | | | | | $ | 0.33 | | | |
December 21, 2028
|
|
| | | | | | 70,324 | | | | | | 4,688(1) | | | | | | — | | | | | $ | 0.33 | | | |
May 1, 2028
|
|
| | | |
Subordinate
Voting Shares |
| |
Multiple
Voting Shares |
| |
Super
Voting Shares |
| |
Total(1)
|
| |
Voting(2) Total
|
| |||||||||||||||||||||||||||||||||||||||
|
Name and Address of Beneficial Owner
|
| |
Number
Beneficially Owned |
| |
% of
Total Subordinate Voting Shares |
| |
Number
Beneficially Owned |
| |
% of
Total Multiple Voting Shares |
| |
Number
Beneficially Owned |
| |
% of
Total Super Voting Shares |
| |
Number of
Capital Stock Beneficially Owned |
| |
% of
Total Capital Stock |
| |
% of
Voting Capital Stock |
| |||||||||||||||||||||||||||
|
Dumont Global LP(3)
|
| | | | 4,545,000 | | | | | | 5.2% | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 4,545,000 | | | | | | 3.5% | | | | | | 2.4% | | |
| NEOs and Directors | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Dr. Kyle E. Kingsley(4)
|
| | | | 5,100,821(3) | | | | | | 5.9% | | | | | | — | | | | | | — | | | | | | 65,411 | | | | | | 100% | | | | | | 11,641,921 | | | | | | 9.1% | | | | | | 37.7% | | |
|
John A. Heller(4)
|
| | | | 657,471 | | | | | | * | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 575,287 | | | | | | * | | | | | | * | | |
|
Christian Gonzalez(4)
|
| | | | 640,660 | | | | | | * | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 581,283 | | | | | | * | | | | | | * | | |
|
Chelsea A. Grayson(4)
|
| | | | 347,489 | | | | | | * | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 347,489 | | | | | | * | | | | | | * | | |
|
Ross M. Hussey(7)
|
| | | | 72,049 | | | | | | * | | | | | | 16,803 | | | | | | 4.8% | | | | | | — | | | | | | — | | | | | | 1,752,349 | | | | | | 1.4% | | | | | | * | | |
|
Victor E. Mancebo(4)
|
| | | | 6,550 | | | | | | * | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 6,550 | | | | | | * | | | | | | * | | |
|
Judd T. Nordquist(7)
|
| | | | 347,489 | | | | | | * | | | | | | 845 | | | | | | * | | | | | | — | | | | | | — | | | | | | 431,989 | | | | | | * | | | | | | * | | |
|
Josh Rosen(5)
|
| | | | 750,014 | | | | | | * | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 750,014 | | | | | | * | | | | | | * | | |
|
Amber H. Shimpa(6)
|
| | | | 2,933,998 | | | | | | 3.4% | | | | | | 8,521 | | | | | | 2.4% | | | | | | — | | | | | | — | | | | | | 3,786,098 | | | | | | 3.0% | | | | | | 2.0% | | |
|
Directors and executive officers as a group (13 persons)(7)
|
| | | | 14,255,715 | | | | | | 16.4% | | | | | | 26,169 | | | | | | 7.4% | | | | | | 65,411 | | | | | | 100% | | | | | | 23,093,673 | | | | | | 18.3% | | | | | | 44.0% | | |
| | | |
2021
|
| |
2020
|
| ||||||
|
Audit Fees
|
| | | $ | 718,120 | | | | | $ | 428,140 | | |
|
Audit-Related Fees(1)
|
| | | $ | — | | | | | $ | 175,364 | | |
|
Tax Fees(2)
|
| | | $ | 28,622 | | | | | $ | 28,489 | | |
|
All Other Fees
|
| | | | — | | | | | | — | | |
|
Total
|
| | | $ | 746,742 | | | | | $ | 641,993 | | |
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|